Anadys

Anadys Pharmaceuticals, a biopharmaceutical company, develops medicines for the treatment of hepatitis C.

Anadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.